RG 101

Drug Profile

RG 101

Alternative Names: RG-101; RG-101Rx

Latest Information Update: 09 Mar 2017

Price : $50

At a glance

  • Originator Stanford University
  • Developer Regulus Therapeutics
  • Class Antisense oligonucleotides; Antivirals; MicroRNAs
  • Mechanism of Action MIRN122 microRNA inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis C

Most Recent Events

  • 02 Mar 2017 Regulus completes the phase II RG-101-02 trial in Hepatitis C (Combination therapy, Treatment-naïve) in Hungary and Greece
  • 02 Mar 2017 Top-line efficacy and adverse events data from the phase II RG-101-02 trial in Hepatitis C released by Regulus Therapeutics
  • 11 Nov 2016 Additional efficacy data from a phase I trial in Hepaitis C presented at the The Liver Meeting® 2016: 67th Annual Meeting of the American Association for the Study of Liver Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top